Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
The battle between JPMorgan’s two flagship covered-call income ETFs comes down to a simple trade-off: JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI) offers the smoother ride, while JPMorgan Nasdaq Equity Premium Income ETF (NASDAQ:JEPQ) delivers the fatter distributions. In July 2026, that trade-off looks less balanced than usual, and the winner may not be the one ... JEPI vs. JEPQ: Which Is the Better Buy in July?
Five Dividend Kings—Procter & Gamble, Hormel, Stanley Black & Decker, Genuine Parts and Lowe's—trade at discounted valuations, offering attractive yields despite near-term business headwinds.
AbbVie will release its second-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.
AbbVie (ABBV) is back in focus after the European Commission granted marketing authorization for Tepkinly plus lenalidomide and rituximab in relapsed or refractory follicular lymphoma, a chemotherapy free bispecific-based regimen for second line treatment. See our latest analysis for AbbVie. Against this backdrop of oncology approvals and index inclusions, AbbVie’s recent momentum is clear, with a 30 day share price return of 12.07% and a 90 day share price return of 20.35%, while 1 year...
While one continues reinvesting for growth, the other has rewarded shareholders for 54 years in a row.
Abivax stock surged over 40% after positive Phase 3 data on ulcerative colitis drug Obefazimod and a $920 million share offering that underwriters fully exercised, signaling strong institutional demand.
Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, royalties and broader pipeline momentum.
AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.
It doesn't get much more dependable and lucrative than the healthcare industry.
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.
Dividend Aristocrats, the S&P 500 companies that have raised payouts for 25 or more consecutive years, remain the bedrock of income portfolios heading into the second half of 2026. Three of them stand out for July: a beaten-down quick-service leader, a biopharma machine firing on all cylinders, and a home improvement giant priced for a ... 3 Dividend Aristocrats to Buy in July
While rivals scramble to replace lost revenue, Lilly is opening an unprecedented gap by being a “contrarian,” as one expert says.
Dividend funds pulled in $24.1 billion in the first quarter of 2026, their strongest opening quarter in four years, and a lot of that cash went looking for a boring place to hide from AI-hype exhaustion. The iShares Core High Dividend ETF (NYSEARCA:HDV) is one of them. HDV holds 75 positions, charges 0.08%, and yields ... A 2.86% Yield, 0.08% Fee, and 75 Stocks: Is HDV the Anti-Hype ETF?
Johnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.
Abivax (ABVX) shares have rebounded to pre-Phase 3 maintenance data levels as investor concerns over
ABBV's Q2 spotlight is on Skyrizi and Rinvoq as rising immunology sales aim to offset Humira's decline ahead of July 31 earnings.
AMAT, MA, ABBV, VATE and BOF headline new research reports highlighting AI, payments, healthcare and microcap growth opportunities.
Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) pays a quarterly distribution from roughly 100 quality-screened U.S. dividend stocks. The fund holds $71.6 billion in assets at an expense ratio of just 0.06%, and it tracks the Dow Jones U.S. Dividend 100 Index, which requires 10 consecutive years of dividend payments and screens on cash flow to ... Six Dividend Aristocrats Keeping SCHD’s Income Stream Bulletproof This Year
U.S. lawmakers have opened a bipartisan national security investigation into AbbVie (NYSE:ABBV) and other pharmaceutical companies. The inquiry focuses on AbbVie’s clinical trials in China, including work at facilities reportedly linked to the Chinese military and sites in the Xinjiang region. Congress has requested detailed information on research practices, data protection, and site vetting, with responses due by mid-July. AbbVie is a large U.S. pharmaceutical company with a portfolio...
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.
The average Social Security retirement check reached $2,081 per month as of April 2026, according to the Social Security Administration’s monthly statistical data. That figure carries the 2.8% cost-of-living adjustment that took effect in January 2026. Replacing roughly that amount with dividend income is a math problem before it is an investing problem, and the ... Social Security Pays $2,081 a Month. Here’s How Much You Need Invested to Match It.
WST has surged nearly 33% YTD as strong earnings, GLP-1 demand and biologics growth fuel momentum that could extend through 2026.
Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index and the State
Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index rising 2% and the S
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
